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a  b  s  t  r  a  c  t
The Global Burden of Disease (GBD) study measures the health of populations worldwide
and  by country on an annual basis and aims at helping guide public policy on health issues.
The  GBD estimates for Spain in 2016 and recent trends in mortality and morbidity from 2006
to  2016 were recently published. According to these estimates, chronic kidney disease was
the 8th cause of death in Spain in 2016. Among the top ten causes of death, chronic kidney
disease was the fastest growing from 2006 to 2016, after Alzheimer disease. At the current
pace  of growth, chronic kidney disease is set to become the second cause of death in Spain,ortality
esearch funding
anking
ublic health
after  Alzheimer disease, by 2100. Additionally, among major causes of death, chronic kidney
disease also ranked second only to Alzheimer as the fastest growing cause of Years Lived
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with Disability (YLDs) and Disability Adjusted Life Years (DALYs). Public resources devoted
to  prevention, care and research on kidney disease should be in line with both its current
and future burden.
© 2018 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Comentario  de  la  Sociedad  Espan˜ola  de  Nefrología  (SENEFRO)  al  informe
GBD  2016  Espan˜a:  mantener  la  enfermedad  renal  crónica  fuera  del  radar
de  las  autoridades  sanitarias  solo  magniﬁcará  el  problema
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r  e  s  u  m  e  n
El estudio Global Burden of Disease (GBD) mide la salud de las poblaciones en todo el mundo
y  en cada país de forma annual, y tiene como objetivo ayudar a orientar las políticas públicas
sobre cuestiones de salud. Recientemente se publicaron las estimaciones GBD 2016 para
Espan˜a  y las tendencias recientes en mortalidad y morbilidad de 2006 a 2016. Según estas
estimaciones, la enfermedad renal crónica fue la octava causa de muerte en Espan˜a en 2016.
Entre las 10 principales causas de muerte, la enfermedad renal crónica fue la que más  creció
entre 2006 y 2016, después de la enfermedad de Alzheimer. Al ritmo actual de crecimiento, la
enfermedad renal crónica se convertirá en la segunda causa de muerte en Espan˜a, después
del  Alzheimer, hacia el 2100. Además, entre las principales causas de muerte, la enfermedad
renal crónica también ocupa el segundo lugar después del Alzheimer como la que más  creció
en  an˜os vividos con discapacidad (AVD) y en an˜os de vida ajustados por discapacidad (AVAD).
Los  recursos públicos dedicados a la prevención, atención e investigación de la enfermedad
renal deberían estar en línea con su carga actual y futura.
©  2018 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Chronic  kidney  disease:  beyond  dialysis,
transplantation  and  chronic  renal  insufﬁciency
The term kidney disease rapidly evokes the concepts of dial-
ysis and transplantation, that is, renal replacement therapy
for end-stage kidney disease. Indeed, the 57,429 persons (i.e.
0.1% of the population) living on dialysis or carrying a kidney
graft in Spain in 2016 are estimated to consume 2–5% of the
healthcare budget.1,2 Spain is a world leader in kidney trans-
plantation and the Organizacion Nacional de Transplantes
(ONT) continuous efforts ensure that this leadership position
is maintained within the evolving public policy and healthcare
frame.3,4 However, the point should not be missed that renal
replacement therapy signals the failure of the healthcare sys-
tem to prevent progression of kidney disease. In this regard,
emphasis has moved in recent years to earlier diagnosis of
kidney disease in order to treat early, thus preventing kidney
disease progression and its potentially lethal complications.
One paradigm shift has been coining the term chronic
kidney disease (CKD). According to the 2012 KDIGO (Kidney
Disease: Improving Global Outcomes) deﬁnition, CKD is diag-
nosed when abnormalities of kidney structure or function are
present for >3 months, with implications for health.5 Thus, the
diagnosis of CKD is made in the presence for over 3 months
of one marker of kidney damage (albuminuria >30 mg/24 h
or >30 mg/g urinary creatinine; or urine sediment abnormal-
ities; or electrolyte and other abnormalities due to tubularby-nc-nd/4.0/).
disorders; or abnormalities detected by histology; or struc-
tural abnormalities detected by imaging; or history of kidney
transplantation) or a decreased glomerular ﬁltration rate (GFR;
GFR <60 ml/min/1.73 m2, GFR categories G3–G5). In this regard,
the CKD concept expands the prior concept of chronic kidney
insufﬁciency that refers to kidney damage that has resulted
in an (unspeciﬁed) decrease in GFR. CKD without renal insuf-
ﬁciency can now be diagnosed solely based on urinary albumin
values. The immediate clinical implication is that in the
absence of albuminuria assessment, CKD cannot be ruled out.
This clearly expands the pool of undiagnosed CKD, since in
primary care, albuminuria assessment is restricted to a few
clinical situations (e.g. diabetes) and even for those situations,
uptake by physicians is not universal. The KDIGO CKD concept
also provides speciﬁc thresholds for eGFR and albuminuria
that allow the diagnosis and categorization of CKD. And now
comes the most interesting part of the CKD concept: these
thresholds are based on epidemiological studies involving mil-
lions of individuals that indicate that the thresholds mark an
increased risk not only of CKD progression to advanced stages,
but also of all-cause and cardiovascular death, as well as of
acute kidney injury.
Thus, the 57,429 Spanish persons on renal replacement
therapy are only the tip of the iceberg of the healthcare con-
sequences of kidney diseases. Over 4 million Spaniards (just
over 10% of the adult population based on a recent SENEFRO
study) have CKD and are at risk of premature death because
of it.6 However, for many  or even most of them, neither the
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Table 1 – Leading causes of death in Spain in 2016 according to GBD and according to INE. The only major difference is
in bold and underlined. INE (Instituto Nacional de Estadística) data were recorded from Basic cause of death statistics.17
(A) Leading causes of death in Spain in 2016 according to GBD 2016
1. Ischemic heart disease
2. Alzheimer disease
3. Stroke
4.  COPD
5.  Lung cancer
6. Colorectal cancer
7. Lower respiratory infection
8. Chronic kidney disease
9. Other cardiovascular
10. Diabetes
(B) Leading causes of death in Spain in 2016 according to INE, simpliﬁed view focused on speciﬁc disorders.
Reference to other “other conditions” removed or associated to main condition based on similarity (e.g. other ischemic heart diseases and
acute myocardial infarction were both included under ischemic heart disease), in an attempt to more closely reﬂect GBD 2016 methods.
Note the absence of chronic kidney disease from the top ten causes of death.
1. Ischemic heart disease
2. Cerebrovascular disease
3. Lung cancer
4. Heart failure
5. Chronic diseases of the lower respiratory tract
6. Alzheimer
7.  Arterial hypertensive diseases
8. Colon cancer
9. Diabetes mellitus
10. Pneumonia
(C) Leading causes of death in Spain in 2016 according to INE (original INE list of major causes of death)
Note that the concept of chronic kidney disease is not even present in the list.
1. Cerebrovascular diseases
2. Other heart diseases
3. Malignant tumor of the trachea, bronchial tube and lungs
4. Organic, senile and presenile mental disorders
5. Other diseases of the respiratory system
6. Heart failure
7. Other ischemic heart diseases
8. Acute myocardial infarction
9. Alzheimer’s disease
10. Chronic diseases of the lower respiratory tracts (except Asthma)
11. Hypertension diseases
12. Other diseases of the digestive system
13. Malignant tumor of the colon
14. Other diseases of the nervous system and sensory organs
15. Diabetes mellitus
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W16. Pneumonia
17. Diseases of the kidney and of the ureter
atient, nor the physician is aware of the CKD diagnosis. It is
hus estimated that the main impact of CKD is not what we
ee (persons on renal replacement therapy) but what we  do
ot see (premature deaths, even before reaching the need for
enal replacement therapy). In this regard, CKD is not usually
isted as a cause of death in CKD patients who die prematurely
ecause of the negative impact of CKD on different organs and
ystems. The Global Burden of Disease study is addressing
uch inconsistencies in the attributable cause of death on a
orldwide basis and for over 200 causes of death.
hat  is  the  GBD  study?he Global Burden of Disease (GBD) initiative of the Institute
or Health Metrics and Evaluation (IHME) at the University of
ashington measures the health of populations worldwideon an annual basis.7 GBD produces age-, sex-, and country-
speciﬁc health estimates using highly standardized, validated
approaches applied to all available data sources and adjusted
for major sources of bias, so as worldwide results are com-
parable. The GBD 2016 report was published in September
2017.8–12 The recent publication of the country-speciﬁc GBD
2016 report provides interesting insights into the current and
future burden of CKD in Spain.13
How  does  the  GBD  study  attribute  the  cause
of  death?The GBD assess cause of death worldwide using a uni-
form methodology that has been extensively detailed in
GBD publications.11,14 Speciﬁcally, it relies on robust statisti-
cal methods including the Cause of Death Ensemble model
 2 0 1 9;3 9(1):29–34
Fig. 1 – Trends in top ten causes of death in Spain,
2006–2016. The top ten causes of death in 2016 in Spain
in terms of number of deaths and their impact on YLDs
and DALYs are shown. (A) % change in number of deaths
2006–2016. (B) % change in number of YLDs 2006–2016.
Data for top ten causes of death in 2016 which are also
among the top 30 causes of YLDs are shown. (C) % change
in number of DALYs 2006–2016. COPD: Chronic Obstructive
Pulmonary Disease; YLDs: Years Lived with Disability;
DALYs: Disability Adjusted Life Years.32  n e f r o l o g i a
(CODEm) to generate estimates for each location, year, age,
and sex. For GBD, each death is attributed to a single under-
lying cause – the cause that initiated the series of events
leading to death – in accordance with International Classiﬁ-
cation of Diseases (ICD) principles.11 The GBD cause of death
list is organized as a hierarchy, with each level composed of
causes of death that are mutually exclusive and collectively
exhaustive. For GBD 2016, separate estimates were developed
for a total of 264 unique causes and cause aggregates. Mul-
tiple sources of data are, for Spain the main source is the
Mortality Information System INEbase of the Spanish National
Institute of Statistics (INE). Cause of death data are then stan-
dardized and processed in a uniform manner. This includes
identifying and redistributing deaths assigned to ICD codes
that cannot be underlying causes of death; are intermediate
causes of death rather than the underlying cause (e.g., sepsis
and heart failure); or lack speciﬁcity in coding. These so-called
garbage codes are redistributed using the GBD method: deaths
coded in this manner were reassigned to likely causes of death
using different approaches.14
What  did  the  GBD  2016  report  for  Spain  say
about  CKD?
According to GBD 2016 estimates, CKD was the 8th cause of
death in Spain in 2016 (Table 1A).13 Among the top ten causes
of death, CKD was the fastest growing from 2006 to 2016, after
Alzheimer disease (Fig. 1A). Additionally, among the top ten
causes of death, it also ranked second only to Alzheimer as
the fastest growing cause of Years Lived with Disability (YLDs)
(Fig. 1B) and Disability Adjusted Life Years (DALYs) (Fig. 1C).
DALYs are the sum of years of potential life lost due to pre-
mature mortality and the years of productive life lost due to
disability. At the current pace, CKD is set to become the second
most frequent cause of death in Spain by 2100, after Alzheimer
disease (Fig. 2).
What  was  known  about  CKD  mortality  in  Spain
until  now?
The main source of health information in Spain is the INE,
which is used to guide public policy.15 We grouped INE causes
of death into a simpliﬁed view, aiming at using the same broad
concepts as in GBD 2016, and identiﬁed ten top causes of death
in 2016 according to INE (Table 1B). All categories of cause of
death present in the top ten GBD 2016 list can be recognized
in the INE ranking, with the exception of CKD. For this sim-
pliﬁed view of INE data, we  did not take into account items
labeled “other”, because of their non-speciﬁc nature and for
example, we  grouped “acute myocardial infarction” together
with “other ischemic heart diseases” in the same category of
“ischemic heart disease”. Overall, the main difference with
the GBD 2016 ranking is the presence of hypertension and
the absence of CKD within the top ten causes of death in the
simpliﬁed INE ranking. The term closest to the CKD concept,
at position eleven (and, thus, not shown in Table 1B) if terms
including “other” are excluded, is a wider category of “diseases
of the kidney and of the ureter”. The fact that one of the top
causes of death, according to the GBD 2016 methodology, ishidden from the view of policy makers may be considered a
major ﬂaw of the INE information system. This indeed may be
one of the reasons for the growing impact of CKD on mortal-
ity, since funding for research and early intervention lags well
behind other major causes of death.
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Fig. 2 – Predicted growth of the top eight causes of death from 2016 to 2100 in Spain, based on growth from 2006 to 2016
according to the GBD 2016 study. Alzheimer is predicted to become the most frequent cause of death by 2026 and is not
represented in the graph due to its magnitude, which would preclude appreciating details for the other causes of death. The
2006–2016 change in number of deaths was extrapolated to predict annual number of deaths up to 2100. COPD: Chronic
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hy  GBD  2016  and  INE  data  do  not  match?
pain GBD 2016 manuscript emphasized discrepancies
etween causes of death for Spain GBD 2016 and data from the
NE that may impact public health policy planning.13 The dis-
repancies between INE and GBD may depend on the different
eﬁnitions used. INE statistics follow the ICD-10 cause of death
ist. In this regard, several GBD 2016 and INE deﬁnitions differ.
s examples, IHD is represented by two different categories
n INE, “Acute myocardial infarction” and “Other ischemic
eart diseases”. Hypertension is considered a garbage code
n GBD and is redistributed to other causes of death. Several
tems labeled “other”, representing several different condi-
ions, made it into the top ten ranking in INE. Overall, all
onditions except one in the top ten causes of death accord-
ng to GBD 2016 can be recognized in a simpliﬁed INE list
Table 1B), the sole exception being CKD. However, the origi-
al ICD-10-based INE rankings differ more  from GBD 2016 data
Table 1C). This may reﬂect the absence of CKD from the ICD-
0 cause-of-death lists as per guidance from the US Centers
or Disease Control And Prevention (CDC),16 where the clos-
st term, included within “diseases of the kidney and of the
reter”, is kidney failure. Kidney failure, according to the cur-
ent consensus international KDIGO 2012 deﬁnition, is applied
o those on or needing renal replacement therapy, and not
o the wider CKD population. Additionally, GBD redistributes
auses of death, so the called garbage codes, as explained
bove, based on a complex algorithm that takes into account
n updated medical literature.11,14
s  Spain  different  from  other  countries  in  terms
f  the  impact  of  CKD  in  mortality?ot really. According to GBD 2016, CKD was the 10th most
requent cause of death worldwide when assessed by the
ge-standardized death rate per 100,000, and together withy; DALYs: Disability Adjusted Life Years.
Alzheimer and diabetes, it was among the three fastest grow-
ing causes of number of deaths or of age-standardized death
rates, and the second fastest growing after Alzheimer in
terms of YLL.11 Indeed, the CKD age-standardized death rate
increased by 28.8% and the YLLs by 21% from 2006 to 2016 on
a worldwide basis.
A  dynamic  versus  a  static  view
In conclusion, the recently published GBD 2016 Spain study
should be a call to action for the medical community, health-
care authorities and the population at large. CKD lags well
behind other major causes of death in terms of resources
devoted to prevention, early therapy and research. Public
resources devoted to prevention, care and research on kidney
disease should be in line with both its current and future bur-
den. Without a signiﬁcant increase in funding for such activity
that dramatically changes the 2006–2016 trend, CKD is set to
become the second cause of death in Spain for future genera-
tions. GBD 2016 data, by providing a time series over the years,
evaluated with the same methodology, standardized and con-
sistent with the methods applied to other countries, provides
a dynamic view of the evolving health landscape in Spain that
allows planning for the future based on worrisome secular
trends like the unrelenting rise of CKD as a major cause of
death.
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